Drug Profile
SU 5271
Latest Information Update: 20 Jul 1999
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antipsoriatics
- Mechanism of Action Epidermal growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 20 Jul 1999 Discontinued-I for Psoriasis in USA (Topical)
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 21 Apr 1997 Phase-I clinical trials for Psoriasis in USA (Topical)